Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document


Zannad, Faiez; Garcia, AngelesAlonso; Anker, StefanD; Armstrong, PaulW; Calvo, Gonzalo; Cleland, JohnGF; Cohn, JayN; Dickstein, Kenneth; Domanski, MichaelJ; Ekman, Inger; Filippatos, GerasimosS; Gheorghiade, Mihai; Hernandez, AdrianF; Jaarsma, Tiny; Koglin, Joerg; Konstam, Marvin; Kupfer, Stuart; Maggioni, AldoP; Mebazaa, Alexandre; Metra, Marco; Nowack, Christina; Pieske, Burkert; Pina, IleanaL; Pocock, StuartJ; Ponikowski, Piotr; Rosano, Giuseppe; Ruilope, LuisM; Ruschitzka, Frank; Severin, Thomas; Solomon, Scott; Stein, Kenneth; Stockbridge, NormanL; Stough, WendyGattis; Swedberg, Karl; Tavazzi, Luigi; Voors, AdriaanA; Wasserman, Scottm; Woehrle, Holger; Zalewski, Andrew; McMurray, JohnJV; (2013) Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European journal of heart failure, 15 (10). pp. 1082-1094. ISSN 1388-9842 DOI: https://doi.org/10.1093/eurjhf/hft095

Full text not available from this repository.

Abstract

Endpoint selection is a critically important step in clinical trial design. It poses major challenges for investigators, regulators, and study sponsors, and it also has important clinical and practical implications for physicians and patients. Clinical outcomes of interest in heart failure trials include all-cause mortality, cause-specific mortality, relevant non-fatal morbidity (e.g. all-cause and cause-specific hospitalization), composites capturing both morbidity and mortality, safety, symptoms, functional capacity, and patient-reported outcomes. Each of these endpoints has strengths and weaknesses that create controversies regarding which is most appropriate in terms of clinical importance, sensitivity, reliability, and consistency. Not surprisingly, a lack of consensus exists within the scientific community regarding the optimal endpoint(s) for both acute and chronic heart failure trials. In an effort to address these issues, the Heart Failure Association of the European Society of Cardiology (HFA-ESC) convened a group of expert heart failure clinical investigators, biostatisticians, regulators, and pharmaceutical industry scientists (Nice, France, 1213 February 2012) to evaluate the challenges of defining heart failure endpoints in clinical trials and to develop a consensus framework. This report summarizes the groups recommendations for achieving common views on heart failure endpoints in clinical trials.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Medical Statistics
Faculty of Public Health and Policy > Dept of Health Services Research and Policy
Academic Services & Administration > Academic Administration
PubMed ID: 23787718
Web of Science ID: 325175700003
URI: http://researchonline.lshtm.ac.uk/id/eprint/1300479

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
359Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item